Amryt Pharma – Shard Capital Update Note

15 March 2017

Amryt Pharma – Shard Capital Update Note

Amryt was established as a platform to acquire, build, develop and commercialise a range of drugs targeted at niche, orphan diseases, thereby creating a Specialty Pharma business. Amryt initially entered into deals with Birken and Som, and more recently has agreed an exclusive commercial licence with Aegerion for Lojuxta, a marketed cholesterol drug targeted at a rare genetic condition, across European and other territories. Amryt is also about to start a Phase III trial with AP101 for Epidermolysis Bullosa in children and adults, having had the protocol accepted by both the EMA and the FDA. This represents a market opportunity of ca.$1.4bn.

Click Here to read Shard’s full research note.